Skip to content
10-K

Annual Report

iTeos Therapeutics, Inc.

0000950170-24-026866

← back to feed
Filed
Mar 6, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Mar 1, 2024 35.84M sh
Shares Diluted FY 2023 · Dec 31, 2022 37.77M sh
Shares Diluted FY 2023 · Dec 31, 2021 37.77M sh
Capex FY 2023 · Dec 31, 2022 $938K
Capex FY 2023 · Dec 31, 2021 $1.18M
Operating Cash Flow FY 2023 · Dec 31, 2022 −$111.19M
Operating Cash Flow FY 2023 · Dec 31, 2021 $513.14M
Short Term Investments FY 2023 · Dec 31, 2022 $328.36M
Cash And Equivalents FY 2023 · Dec 31, 2022 $284.8M
Current Liabilities FY 2023 · Dec 31, 2022 $42M
Total Liabilities FY 2023 · Dec 31, 2022 $91.66M
Current Assets FY 2023 · Dec 31, 2022 $628.3M
Total Assets FY 2023 · Dec 31, 2022 $754.99M
Eps Diluted FY 2023 · Dec 31, 2022 $2.56
Eps Diluted FY 2023 · Dec 31, 2021 $5.68
Eps Basic FY 2023 · Dec 31, 2022 $2.72
Eps Basic FY 2023 · Dec 31, 2021 $6.10
Sga Expense FY 2023 · Dec 31, 2022 $43.95M
Sga Expense FY 2023 · Dec 31, 2021 $40.51M
Rd Expense FY 2023 · Dec 31, 2022 $97.36M
Rd Expense FY 2023 · Dec 31, 2021 $59.37M
Net Income FY 2023 · Dec 31, 2022 $96.65M
Net Income FY 2023 · Dec 31, 2021 $214.52M
Operating Income FY 2023 · Dec 31, 2022 $126.32M
Operating Income FY 2023 · Dec 31, 2021 $244.9M
Revenue FY 2023 · Dec 31, 2022 $267.63M
Revenue FY 2023 · Dec 31, 2021 $344.78M
Stockholders Equity FY 2023 · Dec 31, 2021 $552.82M
Stockholders Equity FY 2023 · Dec 31, 2020 $323.2M